Filing Details

 

 

	UNITED STATES
	SECURITIES AND EXCHANGE COMMISSION
	Washington, DC 20549
	SCHEDULE 13D/A [Rule 13d-101]

 

Information to be Included in Statements Filed Pursuant to §240.13d-1(a)

and Amendments Thereto Filed Pursuant to §240.13d-2(a)

 

(Amendment No. 3)

 

ULURU INC.

(Name of Issuer)

 

COMMON STOCK, PAR VALUE $0.001 PER SHARE

(Title of Class of Securities)

 

90403T209

(CUSIP Number)

 

Michael I. Sacks

c/o Wiggin and Dana LLP

Attn: Scott L. Kaufman

450 Lexington Avenue

New York, NY 10017

(212) 551-2600

(Name, Address and Telephone Number of Person

Authorized to Receive Notices and Communications)

 

March 29, 2016

(Date of Event Which Requires Filing of this Statement)

 

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box o.

 

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits.  See §240.13d-7 for other parties to whom copies are to be sent.

 

* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

 

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

CUSIP No. 90403T209

SCHEDULE 13D/A

 

	1.	Names of Reporting Persons Michael I. Sacks
	2.	Check the Appropriate Box if a Member of a Group (see instructions)
		(a)		x
		(b)		o
	3.	SEC Use Only
	4.	Source of Funds (see instructions) PF
	5.	Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)    o
	6.	Citizenship or Place of Organization South Africa
Number of Shares Beneficially Owned by Each Reporting Person With:			7.	Sole Voting Power 30,050,490
			8.	Shared Voting Power 0
			9.	Sole Dispositive Power 30,050,490
			10.	Shared Dispositive Power 0
	11.	Aggregate Amount Beneficially Owned by Each Reporting Person 30,050,490
	12.	Check if the Aggregate Amount in Row (11) Excludes Certain Shares (see instructions)  o
	13.	Percent of Class Represented by Amount in Row (11) 39.0%1
	14.	Type of Reporting Person (see instructions) IN

 

¹ Based upon 62,974,431 shares of Common Stock outstanding as of March 30, 2016, as provided to the Reporting Person by ULURU Inc. This number of outstanding shares gives effect to the issuance of 25,245,442 shares of Common Stock by ULURU Inc. under the Stock Purchase Agreement, dated as of March 29, 2016 (the “2016 Stock Purchase Agreement”), and does not include shares underlying the warrants issued under this agreement or any other outstanding derivative securities. In accordance with SEC Rule 13d-3, the shares reported as owned by the Reporting Person and the percentage ownership of the Reporting Person assume that the shares underlying the warrant to purchase 14,025,245 shares of Common Stock acquired by the Reporting Person under the 2016 Stock Purchase Agreement are deemed issued to the Reporting Person (and increase the number of shares of Common Stock deemed to be outstanding) but all other warrants issued under the 2016 Stock Purchase Agreement remain unexercised.

 

 

CUSIP No. 90403T209

SCHEDULE 13D/A

 

This Amendment No.3 to Schedule 13D (this “Amendment No. 3”) is filed by Michael I. Sacks (“M Sacks”) with respect to ownership of shares of the common stock, par value $0.001 per share (the “Common Stock”), of ULURU Inc., a Nevada corporation (“ULURU”), and amends and supplements the Schedule 13D filed on February 5, 2014, as amended by Amendment No. 1 filed on April 2, 2015 and Amendment No. 2 filed on July 29, 2015 (the “Original Schedule 13D” and together with this Amendment No. 3, the “Schedule 13D”). Capitalized terms used herein and not otherwise defined in this Amendment No. 3 shall have the meanings set forth in the Original Schedule 13D.

 

This Amendment No. 3 is being filed to amend Items 4, 5, 6 and 7 of the Schedule 13D as follows:

 

Item 4. Purpose of Transaction.

Item 4 of the Schedule 13D is amended and supplemented as follows:

 

M Sacks, Centric Capital Ventures LLC, a Delaware limited liability company (“Centric Capital”), certain other investors (the “Other Investors”) and ULURU entered into a Stock Purchase Agreement, dated as of March 29, 2016 (the “2016 Stock Purchase Agreement”), with respect to the sale by the Company of $1.8 million of shares of Common Stock, together with warrants to purchase one share of Common Stock for each share of Common Stock purchased under the 2016 Stock Purchase Agreement. Under the 2016 Stock Purchase Agreement, M Sacks purchased 14,025,245 shares of Common Stock and Centric Capital purchased 266,480 shares of Common Stock at a purchase price of $0.0713 per share, for an aggregate purchase price of $1.0 million and $19,000, respectively. The closing under the 2016 Stock Purchase Agreement was held on March 30, 2016. In connection with the purchase of shares of Common Stock under the 2016 Stock Purchase Agreement, ULURU issued to M Sacks, for no additional consideration, a warrant to purchase 14,025,245 shares of Common Stock at an exercise price of $0.0871 per share (the “Sacks Warrant”) and issued to Centric Capital, for no additional consideration, a warrant to purchase 266,480 shares of Common Stock at an exercise price of $0.0871 per share (the “Centric Warrant,” and together with the Sacks Warrant, the “Warrants”). The Warrants will be exercisable at any time, and from time to time, in whole or in part, through March 30, 2021.

The terms of the 2016 Stock Purchase Agreement and the Warrants, including the purchase price for the shares of Common Stock purchased thereunder and the exercise price, were set by ULURU and certain Other Investors. Neither M Sacks, Centric Capital nor Bradley J. Sacks (“B Sacks”), the Chairman of the Board of Directors of ULURU, Managing Member of Centric Capital, and the son of M Sacks, was involved with such negotiations.

 

 

 

Other than as described above or elsewhere in this Schedule 13D, M Sacks does not have any present plans or proposals that relate to or would result in any of the actions described in subparagraphs (a) through (j) of Item 4 of Schedule 13D, although M Sacks may, at any time and from time to time, review or reconsider his position and/or change his purpose and/or formulate plans or proposals with respect thereto.

 

Item 5. Interest in Securities of the Issuer.

 Item 5(a), (b) and (c) of the Schedule 13D are amended and supplemented as follows:

 (a)     M Sacks beneficially owns 30,050,490 shares of Common Stock, which includes 14,025,245 shares of Common Stock issuable upon exercise of the Sacks Warrant, representing 39.0% of the outstanding shares of Common Stock.

Centric Capital directly beneficially owns 552,960 shares of Common Stock, which includes 266,480 shares of Common Stock issuable upon exercise of the Centric Warrant, and by virtue of his control of Centric Capital as its Managing Member, B Sacks is deemed to beneficially own such 552,960 shares of Common Stock, representing 0.9% of the outstanding shares of Common Stock.

 

The foregoing percentages are based upon 62,974,431 shares of Common Stock outstanding as of March 30, 2016, as provided to M Sacks by ULURU. This number of outstanding shares gives effect to the issuance of 25,245,442 shares of Common Stock by ULURU under the 2016 Stock Purchase Agreement and does not include shares underlying the warrants issued under this agreement or any other outstanding derivative securities. In accordance with SEC Rule 13d-3, the shares reported as owned by M Sacks and the percentage ownership of M Sacks assume that the shares underlying the Sacks Warrant are deemed issued to M Sacks (and increase the number of shares of Common Stock deemed to be outstanding) but all other warrants issued under the 2016 Stock Purchase Agreement remain unexercised.

 

M Sacks disclaims any beneficial ownership or pecuniary interest in the shares of Common Stock beneficially owned by B Sacks or Centric Capital.  Any information regarding B Sacks or Centric Capital described in this Schedule 13D is based on information provided by B Sacks and Centric Capital to M Sacks.

 

M Sacks, B Sacks and Centric Capital may be deemed to be a “group” within the meaning of Rule 13d-5(b) under the Exchange Act.

 

 (b)         M Sacks has sole voting and dispositive power with respect to the 30,050,490 shares of Common Stock he beneficially owns, which includes 14,025,245 shares of Common Stock issuable upon exercise of the Sacks Warrant.

Centric Capital has sole voting and dispositive power over 552,960 shares of Common Stock, which includes 266,480 shares of Common Stock issuable upon exercise of the Centric Warrant, which shares are deemed to be beneficially owned by B Sacks by virtue of his control of Centric Capital as its Managing Member.

 

 

 

(c)           Except as described in Item 4 of this Amendment No. 3, no transactions in the shares of Common Stock have been effected by M Sacks during the past 60 days and to the knowledge of M Sacks, no transactions in the shares of Common Stock have been effected by B Sacks or Centric Capital during the past 60 days.  

Item 6.   Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer.

 

Item 6 of the Schedule 13D is hereby amended by adding thereto the information contained in Items 4 and 5 of this Amendment No. 3 and as follows:

 

References to and descriptions of the 2016 Stock Purchase Agreement and the Warrants included in this Schedule 13D do not purport to be complete and are qualified in their entirety by reference to the full text of such agreement and the form of Warrant attached hereto as Exhibits 99.1 and 99.2, and each is incorporated herein by this reference.

 

Item 7.  Material to be Filed as Exhibits.

 

99.1

Stock Purchase Agreement dated as of March 29, 2016 by and between ULURU Inc. and the investors who have executed a counterpart signature page thereto.

 

99.2

Form of ULURU Inc. Common Stock Purchase Warrant

 

 

 

CUSIP No. 90403T209

SCHEDULE 13D/A

 

SIGNATURE

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

Dated: April 1, 2016
		/s/ Michael I. Sacks
		Michael I. Sacks